Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People

NACompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Vaccination with FAB-3511

One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

BIOLOGICAL

Vaccination with FAB-6011

One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

BIOLOGICAL

Vaccination with FAB-9011

One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

BIOLOGICAL

Vaccination with FluvalAB

One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

Trial Locations (4)

1083

Family Doctor's Office, Budapest

1136

Family Doctor's Office, Budapest

2000

Family Doctor's Office, Szentendre

2120

Family Doctor's Office, Dunakeszi

All Listed Sponsors
lead

Fluart Innovative Vaccine Ltd, Hungary

INDUSTRY